Dr. Mark Yoder, M.D.
Pulmonology (Pulmonary Disease Physician)
1725 W Harrison St, Pob 054
Chicago, IL 60612
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 655
Licensed in Illinois since 2000, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
IL license 036-102363 (first issued 2000; active) -
Critical Care Medicine (Internal Medicine) Physician
IL license 036-102363 (first issued 2000; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Rush University Medical Center Chicago, IL
- Rush Oak PArk Hospital Oak PArk, IL
Medical groups
- Rush University Medical Group (1,551 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 655
- Services billed
- 1,869
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Test to measure rate of airflow | 408 | 364 |
| Test to examine how well the lungs exchange gases | 367 | 362 |
| Test to determine lung volumes using sensors | 353 | 349 |
| Established patient office or other outpatient visit, 30-39 minutes | 192 | 139 |
| Telephone medical discussion with physician, 21-30 minutes | 140 | 119 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 134 | 133 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 100 | 71 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 98 | 56 |
| Critical care, first 30-74 minutes | 83 | 31 |
| New patient office or other outpatient visit, 45-59 minutes | 31 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Azithromycin Other prescribers in Chicago, IL | 209 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Chicago, IL | 197 |
| Prednisone Other prescribers in Chicago, IL | 166 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Chicago, IL | 153 |
| Montelukast Sodium Other prescribers in Chicago, IL | 128 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Chicago, IL | 88 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Chicago, IL | 88 |
| Mycophenolate Mofetil Other prescribers in Chicago, IL | 57 |
| Azelastine Hcl Other prescribers in Chicago, IL | 57 |
| Pantoprazole Sodium Other prescribers in Chicago, IL | 51 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $20,516 in research payments for these studies, mostly to the institutions running them.
- Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
United Therapeutics Corporation · Recruiting · NCT05943535 - Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation · Completed · NCT04708782
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.